BioGenes - antibody development with new technology platform
BioGenes GmbH announced the successful completion of a first step of an intended technological innovation. During a comprehensive R&D process the company has significantly optimised the well-known standard mouse hybridoma technology. As a result BioGenes has now an innovative technology platform at its disposal which enables the company to produce antibodies much more efficiently and economical.
With the new platform BioGenes extends and improves its service offer especially for those customers only having a very small amount of antigen and little time for the project also. In contradiction to competitors stable clones (IgG) will be available within 3-4 months. The delivery of all positive stable clones to their customers has been a long-time company standard just like the fact that all project results as well as clones are of course their customer's property. The company now focuses on the further perfection of the technology. In consequence they will be in the position to provide their customers once more with enhanced first-class services.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.